Standard BioTools Inc [NASDAQ: LAB] stock went on a downward path that fall over 0.00% on Tuesday, amounting to a one-week price increase of more than 14.52%.
Over the last 12 months, LAB stock dropped by -18.86%. The one-year Standard BioTools Inc stock forecast points to a potential upside of 8.39. The average equity rating for LAB stock is currently 2.33, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $546.08 million, with 383.61 million shares outstanding and 368.40 million shares in the current float. Compared to the average trading volume of 1.46M shares, LAB stock reached a trading volume of 11149155 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Standard BioTools Inc [LAB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LAB shares is $1.55 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LAB stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Standard BioTools Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 13, 2025. The new note on the price target was released on February 27, 2025, representing the official price target for Standard BioTools Inc stock. Previously, the target price had yet another raise to $3.50, while TD Cowen analysts kept a Buy rating on LAB stock.
The Price to Book ratio for the last quarter was 1.36, with the Price to Cash per share for the same quarter was set at 0.51.
LAB Stock Performance Analysis:
Standard BioTools Inc [LAB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.52. With this latest performance, LAB shares gained by 7.58% in over the last four-week period, additionally plugging by 30.28% over the last 6 months – not to mention a drop of -18.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LAB stock in for the last two-week period is set at 65.96, with the RSI for the last a single of trading hit 0.0924, and the three-weeks RSI is set at 0.0851 for Standard BioTools Inc [LAB]. The present Moving Average for the last 50 days of trading for this stock 1.2866, while it was recorded at 1.3560 for the last single week of trading, and 1.2205 for the last 200 days.
Insight into Standard BioTools Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Standard BioTools Inc [LAB] shares currently have an operating margin of -83.21% and a Gross Margin at 46.52%. Standard BioTools Inc’s Net Margin is presently recorded at -99.55%.
Standard BioTools Inc (LAB) Capital Structure & Debt Analysis
According to recent financial data for Standard BioTools Inc. ( LAB), the Return on Equity (ROE) stands at -24.63%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -17.93%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Standard BioTools Inc’s Return on Invested Capital (ROIC) is -30.40%, showcasing its effectiveness in deploying capital for earnings.
Standard BioTools Inc (LAB) Efficiency & Liquidity Metrics
Based on Standard BioTools Inc’s (LAB) latest financial statements, the Debt-to-Equity Ratio is 0.07%, indicating its reliance on debt financing relative to shareholder equity.
Standard BioTools Inc (LAB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Standard BioTools Inc. (LAB) effectively leverages its workforce, generating an average of -$156784.84 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.38% and a Quick Ratio of 4.14%, indicating strong ability to cover short-term liabilities.
LAB Stock EPS
With the latest financial reports released by the company, Standard BioTools Inc posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LAB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Standard BioTools Inc go to 42.89%.
Standard BioTools Inc [LAB] Institutonal Ownership Details
There are presently around $74.68%, or 76.71%% of LAB stock, in the hands of institutional investors. The top three institutional holders of LAB stocks are: CASDIN CAPITAL, LLC with ownership of 63.96 million shares, which is approximately 17.1782%. VIKING GLOBAL INVESTORS LP, holding 58.65 million shares of the stock with an approximate value of $$103.81 million in LAB stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$38.5 million in LAB stock with ownership which is approximately 5.8424%.
